FDA proposes reclassifying hepatitis B assays
The FDA plans to move the assays from higher-risk class III devices to class II, making them eligible for the 510(k) pathway.
Uncategorized
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to Expand Pipeline
While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to Expand Pipeline Read More »
AI Return on Investment: Just Because We Can, Should We?
In this episode, Lori and guests continue their exploratory discussion on AI and focus on the challenges of globalization and return on investment.
AI Return on Investment: Just Because We Can, Should We? Read More »
ARCH Fuels Up With $3B to Support Next Class of AI Biotechs
ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to support brand new startups working with AI.
ARCH Fuels Up With $3B to Support Next Class of AI Biotechs Read More »
Telling the Right Story: Overselling, Underselling Can Hurt Your Candidacy
During the job application and interview process, candidates who lie to prospective employers and those who don’t properly highlight their accomplishments can find it difficult to land—or keep—their next role. We asked experts how to sell yourself positively and honestly.
Telling the Right Story: Overselling, Underselling Can Hurt Your Candidacy Read More »
Study Casts Doubt on Benefit of Anti-CD20 Therapies in Multiple Sclerosis
New research has found that MS patients treated with anti-CD20 antibodies, such as Roche’s Ocrevus, do not experience significantly slower progression of disability.
Study Casts Doubt on Benefit of Anti-CD20 Therapies in Multiple Sclerosis Read More »
Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics
A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.
Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics Read More »
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in patients with sickle cell disease. Guggenheim Securities analysts said the setback increases investor frustrations with the company’s business development track record.
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death Read More »
¿Cuánto cuesta una farmacia en Madrid?
La mayoría de los estudiantes de Farmacia que acaban de obtener sus títulos, sueñan con convertirse en los titulares de su propio negocio. Pero mientras algunos lo tienen fácil por continuar la tradición familiar, otros tienen que enfrentarse a un panorama bastante …
Un protocolo para estudiar el síndrome de fatiga crónica
El síndrome de fatiga crónica es un síndrome neurológico con repercusión en diversos sistemas orgánicos y altamente discapacitante, que refleja una situación de fatigabilidad persistente e inexplicada a pequeños esfuerzos tanto físicos c …
Un protocolo para estudiar el síndrome de fatiga crónica Read More »